# SmartZyme BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/smartzyme-biopharma

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.smzyme.com
- Latest round: Series B (Mar 14, 2018)
- Investors on record: 2

## About

SmartZyme BioPharma, Inc. specializes in the development of glycan-based therapeutics and bioconjugation technologies, driving advancements in glycobiology for cancer diagnostics and vaccine development.Founded in 2013, SmartZyme BioPharma, Inc. is headquartered in New York, US. The company focuses on glycan-based therapeutics and bioconjugation technologies. SmartZyme has engaged in two deals, with its most recent funding round occurring on March 14, 2018, where it raised USD 4.00 mn, led by OrbiMed Advisors. This funding was part of the first tranche of Series B financing.SmartZyme BioPharma, Ltd. specializes in developing glycan-based therapeutics and bioconjugation technologies, focusing on glycobiology. Their core offerings include assay kits, enzymes, and recombinant proteins aimed at facilitating glycoproteomic analysis and vaccine development. The company serves a diverse clientele, including research institutions, pharmaceutical companies, and biotechnology firms across North America, Europe, and Asia, addressing challenges in immuno-oncology and vaccine advancement.SmartZyme BioPharma operates a B2B business model, generating revenue through direct sales of specialized products such as assay kits and enzymes, sold individually or in bulk to institutional clients. The company may also form partnerships that provide exclusive access to certain technologies, increasing market reach and customer loyalty. Pricing plans are aligned with the scientific and commercial needs of clients, supporting their competitive positioning in the biotech industry.SmartZyme BioPharma plans to leverage the recent funding raised on March 14, 2018, to support upcoming product launches and expand its market presence. The company is developing new products focused on glycan-based therapeutics, which are anticipated to enhance their offerings. Additionally, SmartZyme aims to penetrate new markets across Europe and Asia by the end of 2023, broadening its geographic footprint and customer base.

## Funding rounds

- Series B, Mar 14, 2018 — OrbiMed Advisors, Virtus Inspire Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series B